Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,326

Document Document Title
WO/2018/206635A1
The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an act...  
WO/2018/197523A1
The invention relates to novel compounds of formula (I) and their use in medicine, particularly in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Additionally, the i...  
WO/2018/178982A8
It is an object of the present invention to provide a novel and advantageous process for commercially preparing of indoxacarb which is racemic or enantiomerically enriched at chiral center from its amide precursor using a new catalytic s...  
WO/2018/178982A1
It is an object of the present invention to provide a novel and advantageous process for commercially preparing of indoxacarb which is racemic or enantiomerically enriched at chiral center from its amide precursor using a new catalytic s...  
WO/2018/157813A1
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...  
WO/2018/137387A1
Provides a crystalline form of indoxacarb, the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. Also provides the use of various...  
WO/2018/120093A1
Provided are a process for preparing an oxadiazacyclo compound and the use thereof. An N-alkoxycarbonyl hydrazine is cyclized with a disubstituted ether under the action of an alkali to give an N-alkoxycarbonyl oxadiazacyclo compound, an...  
WO/2018/093920A1
The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the natural...  
WO/2018/089951A1
Chemoselective conjugation is achieved through redox reactivity by reacting an N- transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Ch...  
WO/2018/039430A1
Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expres...  
WO/2018/011673A3
The present disclosure relates to 1, 3, 5-dioxazine derivatives of formula (I) capable of reducing or eliminating hydrogen sulfide and other objectionable sulfides from oil field produced hydrocarbon fluids such as petroleum, fuel oil, g...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2017/202481A1
The invention relates to the use of l-(4,6-dipentyl-5,6- dihydro-2H-l,2,3-oxadiazin-2-yl)-3-hydroxypropan-l-one in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Add...  
WO/2017/194452A1
The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, ...  
WO/2017/156074A1
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or medi...  
WO/2017/116702A1
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used fo...  
WO/2017/101553A1
Disclosed are a fluorene multifunctional photoinitiator as represented by general formula (I), a photosensitive resin composition containing same, and the preparation thereof and uses of the two. The compound has the advantages of simple...  
WO/2017/031325A1
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...  
WO/2017/030728A1
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.  
WO/2016/201168A1
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...  
WO/2016/193822A1
A process for preparing (E)-(5,6-dihydro-l,4,2-dioxazin-3-yl)(2- hydroxyphenyl)methanone O-methyl oxime is described which includes: (i) reacting benzofuran-3(2H)-one O-methyl oxime (1) with at least one nitrite selected from n-butyl nit...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/187534A1
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasi...  
WO/2016/106284A3
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...  
WO/2016/106284A2
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...  
WO/2016/040458A3
18F labeled ID01 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a l-fluoro-2-halo-4- aminobenzene and a 4-amino-N-hydroxy-l,2,5-oxadiazole-3-carboximidoyl chlorid...  
WO/2016/040458A2
18F labeled ID01 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a l-fluoro-2-halo-4- aminobenzene and a 4-amino-N-hydroxy-l,2,5-oxadiazole-3-carboximidoyl chlorid...  
WO/2015/195686A1
A polyoctatriazacane molecule is disclosed that has a plurality of octatriazacane groups having the structure (I); and a plurality of divalent bridging groups, each divalent bridging group comprising an aromatic group.  
WO/2015/155230A1
The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates fr...  
WO/2015/078116A1
The present invention relates to a process for preparing isocyanate homopolymers containing uretdione groups, in which the phosphinoboron compound of formula (I) are used as catalysts to catalyze the homopolymerization reaction of raw is...  
WO/2015/033303A1
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The i...  
WO/2015/011071A1
The present invention relates to a process for producing polyisocyanates containing iminooxadiazinedione groups, by oligomerizing at least one monomeric di- and/or triisocyanate in the presence of a) at least one catalyst, b) at least on...  
WO/2015/011068A1
The present invention relates to a method for producing polyisocyanates which contain iminooxadiazine dione groups and in which at least one monomeric di- and/or triisocyanate is oligomerized in the presence of at least one catalyst and ...  
WO/2015/011069A1
The invention relates to a method for producing polyisocyanates-containing iminooxadiazinedione groups, wherein at least one monomeric di- and/or triisocyanate is oligomerized in the presence of a) at least one catalyst, b) at least one ...  
WO/2014/202697A1
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of preparation and uses thereof, pharmaceutical compositions in particular to be used as chitinase inhibitors in the treatment of a fungal infection.  
WO/2014/198620A1
The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrin...  
WO/2014/147231A1
The application relates to a catalyst kit comprising a trimerization catalyst for the asymmetric trimerization of polyisocyanates and a catalyst poison for the trimerization catalyst, which is characterized in that the trimerization cata...  
WO/2014/078690A1
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.  
WO/2014/074365A1
The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridem...  
WO/2014/069620A1
The present invention is a method for producing a liquid composition with a pH of 10.0 or more comprising tetrahydro-4H-1,3,5-oxadiazine-4-one and water by reacting urea and formaldehyde in water, the molar feed ratio of formaldehyde/ure...  
WO/2014/040709A1
The present invention relates to a compound of formula (1) wherein X1 represents O or NR6, X2 represents O or NR6, X3 represents O or NR1, R1 represents H or C1 to C3 alkyl, R2 represents H, or a linear or branched C1 - C8 alkyl optional...  
WO/2014/028669A1
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma rec...  
WO/2013/187480A1
An aim of the present invention is to provide a novel cyclic depsipeptide derivative and a pest control agent comprising the same. According to the present invention, a compound represented by formula (1) or a stereoisomer thereof, a pes...  
WO/2013/184734A1
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.  
WO/2013/172171A1
A cyclic carbodiimide compound represented by formulas (O-1) or (O-2) can be used for producing a polyester film that does not contain isocyanates with a small molecular weight and that has excellent thickness uniformity without any thic...  
WO/2013/139697A1
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...  
WO/2013/119184A1
The invention relates to the synthesis of peptides, proteins and related bioconjugates, and in particular, to such synthesis using a peptide ligation method whereby a C-terminal salicylaldehyde ester peptide is reacted with an aminoacyl-...  
WO/2013/115884A3
Provided herein are novel small molecule pyridomyrimidone viral inhibitor agents of Formula (I), such as 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[l,2-f]pyrimidin-1 -one, and methods of using pharmaceutical or therapeutic compositions c...  
WO/2013/116682A1
The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of ...  
WO/2013/104613A1
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  

Matches 1 - 50 out of 1,326